The three proteasome inhibitors which downregulated MYC expression in HLRCC tumor cells (Fig. 4C), also decreased the expression of GLS and GLS2 (Fig. 5B). This evidence concerns the gene MYC and hereditary leiomyomatosis and renal cell cancer.